ALK and anaplastic large cell lymphoma: Here, we report the case of a 13-year-old boy with CD30 + /ALK + ALCL who failed to achieve remission after conventional multiagent chemotherapy and experienced a rapid disease progression, despite a second-line treatment with brentuximab-vedotin, steroids and vinblastine.